<DOC>
	<DOCNO>NCT02089087</DOCNO>
	<brief_summary>This first-in-human study investigate safety , tolerability , pharmacokinetics , pharmacodynamics single intravenous subcutaneous dos CFZ533 healthy subject intravenous dos rheumatoid arthritis patient .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single Dose CFZ533 Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>This Healthy Volunteer study originally , amendment protocol , rheumatoid arthritis patient start 7-Mar-2014 thus , protocol register .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion Criteria ( healthy volunteer ) : 1 . Healthy male surgically sterilize postmenopausal female subject 18 55 year age ( Cohort 9 , subject must Chinese descent ) 2 . Vital sign ( systolic diastolic blood pressure pulse rate ) within normal limit 3 . Weight 50150 kg body mass index ( BMI ) 1832 kg/m2 Inclusion Criteria ( rheumatoid arthritis patient ) : 1 . Healthy male surgically sterilize postmenopausal female subject 18 55 year age 2 . Fulfilled 2010 ACR/EULAR classification criterion RA per Investigator 3 . Treatment stable oral RA treatment regimen ≥ 4 week randomization 4 . Systemic corticosteroid allow stable dose ( ≤ 10 mg/day prednisone equivalent ) ≥ 4 week prior randomization 5 . Subjects take NSAIDs ( COX1 COX2 inhibitor ) part RA therapy must stable dose least 4 week randomization Exclusion Criteria ( healthy volunteer ) : 1 . History hypersensitivity vaccine , study drug , drug similar chemical class ( i.e. , biologic agent ) 2 . Abnormal hematology , coagulation inflammatory lab result 3 . History evidence tuberculosis . Exclusion Criteria ( rheumatoid arthritis patient ) : 1 . Use antiTNF biologics previous 3 month 2 . Any intraarticular injection therapy ( e.g. , corticosteroid , hyaluronan ) require treatment acute RA flare within 4 week randomization 3 . Previous treatment B celldepleting biologic agent immunomodulatory biologic agent within 5 halflives ( experimental approve ) 4 . Current treatment cyclophosphamide 5 . Autoimmune disease RA 6 . Adult juvenile rheumatoid arthritis 7 . RA functional status class IV accord ACR 1991 revise criterion Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid arthritis , RA , first-in-human , single ascend dose , safety , tolerability</keyword>
</DOC>